FertilAI, a Tel Aviv, Israel-based company that provides doctors with critical AI-driven patient insights, raised $4.5M in funding.
The round was led by Longevity Venture Partners and Redseed with additional investment from angel investors.
The company intends to use the funds to invest in market expansion, personnel, and reinforcing R&D efforts.
Led by CEO Rohi Hourvitz, FertilAI focuses on making fertility treatments and provides an AI-based Fertilane platform that integrates with clinic electronic medical records (EMRs) to improve predictability, clinical outcomes, and the patient experience throughout the fertility journey, from identifying optimal embryo transfer timing and optimizing decision-making throughout the stimulation cycle to ovulation tracking, supporting timed intercourse, and facilitating intrauterine insemination (IUI). Furthermore, the mobile patient app improves two-way communication between clinic and patients.
In 2024 alone, the product has been used globally by more than 50 physicians across 20,000+ patients.Ā
FinSMEs
20/11/2024